190 related articles for article (PubMed ID: 19581310)
1. The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.
Onal C; Topkan E; Efe E; Yavuz M; Arslan G; Yavuz A
Br J Radiol; 2009 Dec; 82(984):1019-26. PubMed ID: 19581310
[TBL] [Abstract][Full Text] [Related]
2. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy.
Sanguineti G; Marcenaro M; Franzone P; Foppiano F; Vitale V
Radiother Oncol; 2003 Feb; 66(2):151-7. PubMed ID: 12648786
[TBL] [Abstract][Full Text] [Related]
4. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?
Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V
Tumori; 2004; 90(2):201-7. PubMed ID: 15237583
[TBL] [Abstract][Full Text] [Related]
5. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.
Hanks GE; Pajak TF; Porter A; Grignon D; Brereton H; Venkatesan V; Horwitz EM; Lawton C; Rosenthal SA; Sandler HM; Shipley WU;
J Clin Oncol; 2003 Nov; 21(21):3972-8. PubMed ID: 14581419
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
[TBL] [Abstract][Full Text] [Related]
7. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer.
Yang FE; Chen GT; Ray P; Vaida F; Chiru P; Hamilton RJ; Spelbring D; Abellera M; Vijayakumar S
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1009-17. PubMed ID: 7493827
[TBL] [Abstract][Full Text] [Related]
8. Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer.
Martinez AA; Yan D; Lockman D; Brabbins D; Kota K; Sharpe M; Jaffray DA; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1226-34. PubMed ID: 11483333
[TBL] [Abstract][Full Text] [Related]
9. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Corn PG; Song DY; Heath E; Maier J; Meyn R; Kuban D; DePetrillo TA; Mathew P
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):540-5. PubMed ID: 23541810
[TBL] [Abstract][Full Text] [Related]
11. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
12. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
13. Anatomic variations due to radical prostatectomy. Impact on target volume definition and dose-volume parameters of rectum and bladder.
Sanguineti G; Castellone P; Foppiano F; Franzone P; Marcenaro M; Tognoni P; Bolognesi A; Ceresoli GL; Fiorino C
Strahlenther Onkol; 2004 Sep; 180(9):563-72. PubMed ID: 15378187
[TBL] [Abstract][Full Text] [Related]
14. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose.
Lilleby W; Dale E; Olsen DR; Gude U; Fosså SD
Acta Oncol; 2003; 42(1):10-4. PubMed ID: 12665325
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of margins in pelvic lymph nodes and prostate radiotherapy and the impact of bladder and rectum on prostate position.
Marnouche EA; Hadadi K; Abdelhak M; Benlemlih M; Hommadi M; Zaghba N; Andaloussi Saghir K; Elmarjany M; Sifat H; Mansouri H
Cancer Radiother; 2021 Apr; 25(2):161-168. PubMed ID: 33454191
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
Perez CA; Michalski JM; Mansur D; Lockett MA
Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
[TBL] [Abstract][Full Text] [Related]
18. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
[TBL] [Abstract][Full Text] [Related]
19. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
Dearnaley DP; Hall E; Lawrence D; Huddart RA; Eeles R; Nutting CM; Gadd J; Warrington A; Bidmead M; Horwich A
Br J Cancer; 2005 Feb; 92(3):488-98. PubMed ID: 15685244
[TBL] [Abstract][Full Text] [Related]
20. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]